Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

Clinical Breast Cancer

Volumn 5, Issue 5, 2004, Pages 348-352

  Harbeck, Nadia ^a   Kates, Ronald E ^a   Schmitt, Manfred ^a   Gauger, Katja ^a   Kiechle, Marion ^a   Jänicke, Fritz ^b   Thomssen, Christoph ^b   Look, Maxime P ^c   Foekens, John A ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant chemotherapy; Clinical response; Disease recurrence; Nodal involvement; Palliative therapy; Prognosis

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GONADORELIN; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; WX UK1;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG RESPONSE; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; METASTASIS; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

EID: 12144261490     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.n.040     Document Type: Review

References (22)

1. Andreasen PA, Kjöller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72:1-22.
2. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78:285-296.
3. Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of uPA/PAI-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002; 3:196-200.
4. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78:1434-1441.
5. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in 8,377 breast cancer patients. J Natl Cancer Inst 2002; 94:116-128.
6. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21:3357-3365.
7. Jänicke F, Prechtl A, Thomssen C, et al. For the German Chemo NO Study Group: randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. J Natl Cancer Inst 2001; 93:913-920.
8. Harbeck N, Meisner C, Prechtl A, et al. For the German Chemo-NO Study Group. Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-NO therapy trial. Breast Cancer Res Treat 2001; 69:213.
9. Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20:1000-1009.
10. Jänicke F, Thomssen C, Pache L, et al. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M, Graeff H, Jä nicke F, eds. Prospects in Diagnosis and Treatment of Cancer. Amsterdam: Elsevier Science; 1994:207-218.
11. Foekens JA, Look MP, Peters HA, et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87:751-756.
12. Pierga JY, Laine-Bidron C, Beuzeboc P, et al. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 1997; 76:537-540.
13. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n=3,424). Cancer Res 2002; 62:4617-4622.
14. Cufer T, Borstnar S, Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 2003; 18:106-115.
15. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88:1456-1466.
16. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
17. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
18. Paik S, Shak S, Tang G, et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients: NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003; 82(suppl 1):S10 (Abstract #16).
19. Schmitt M, Wilhelm OG, Reuning U, et al. The plasminogen activation system as a novel target for therapeutic strategies. Fibrinolysis 2000; 14:114-132.
20. Muehlenweg B, Sperl S, Magdolen V, et al. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumors. Exp Opin Biol Ther 2001; 1:683-691.
21. Wilex Reports Positive Phase Ia Clinical Data on its Anti-Metastatic Urokinase Inhibitor WX-UK1. Located at: www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY= /www/story/03-18-2002/0001688348. Accessed January 10, 2004.
22. Fox Chase Cancer Center and Wilex Awarded First Biotechnology Clinical Partnership Grant from Department of Defense Breast Cancer Research Program. Located at: www.fccc.edu/news/2003 /Biotechnology-Clinical-Partnership-Grant-09-04-2003.html. Accessed January 12, 2004.